Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments, we spoke with the Chief Financial Officer Mirit Horenshtein Hadar about the company’s achievements and strategic direction. Hadar, who previously served as CFO of Gauzy Israel (NASDAQ: GAUZ) and has held senior finance positions at pharmaceutical and technology companies, making her no stranger to the pharma or capital markets landscapes.
Advancing RNAi Platform: SIL204 Leads the Way
Building on the clinical success of its first-generation LODER™ platform, which demonstrated a 56% objective response rate and 9.3-month survival improvement in Phase 2 trials for non-resectable pancreatic cancer, Silexion’s most exciting scientific advancements have come from its next-generation siRNA candidate, SIL204. This innovative therapy has shown impressive results in preclinical studies throughout 2024 and early 2025.
“Our preclinical progress with SIL204 has been particularly encouraging,” said Hadar. “The breakthrough findings from orthotopic pancreatic cancer models show SIL204’s ability to significantly reduce both primary tumor burden and metastatic spread when administered systemically.”
These recent studies evaluated SIL204 in clinically relevant orthotopic models, where human pancreatic tumor cells are implanted directly into the pancreas to better mimic human disease progression. Such models provide substantially more translational value than standard subcutaneous xenograft models, as they replicate both the complex microenvironment of pancreatic tumors and their characteristic metastatic behavior.
“In the AsPC-1 model with its KRAS G12D mutation, we observed approximately 70% reduction in tumor cell activity compared to the control group,” Hadar explained. “With Panc-1, another cell line harboring KRAS G12D, we saw tumor cell numbers decrease dramatically in a dose-dependent manner, with statistically significant results.” The BxPC-3 model showed even more impressive effects, with up to 80% reduction in tumor activity.
Perhaps most importantly, the studies demonstrated SIL204’s ability to reduce metastatic spread to secondary organs—the first time Silexion has validated this effect in metastatic models.
“The ability to address both primary tumors and their metastases through systemic administration represents a significant potential advantage in treating aggressive diseases like pancreatic cancer,” noted Hadar. “What’s particularly exciting about SIL204 is its ability to target a broader range of KRAS mutations and its potential for systemic delivery, which could substantially expand the therapy’s applications beyond what we’ve achieved with LODER.”
Expanding Development Strategy
Based on the promising results from both programs, Silexion has been actively developing an expanded strategy for its pipeline. The company recently announced the completion of this expanded development plan for SIL204, which will be presented at the upcoming NeauxCancer Conference in New Orleans.
“We’ve finalized our expanded development plan for SIL204, which builds upon our recent preclinical successes,” said Hadar. “The plan is designed to maximize SIL204’s potential across multiple delivery approaches to address the challenges of KRAS-driven cancers.”
While specific details will be unveiled at the conference, Silexion has confirmed its intention to advance SIL204 toward Phase 2/3 clinical trials by the first half of 2026, initially targeting locally advanced pancreatic cancer. The company also plans to initiate preclinical studies in colorectal cancer models, expanding SIL204’s potential applications across additional KRAS-driven cancers.
“Our strategic vision encompasses not just pancreatic cancer, but potentially other KRAS-driven malignancies where our unique RNAi approach could make a significant difference,” Hadar emphasized.
Financial Position to Support Development
Following its public listing in August 2024, Silexion has strengthened its financial position through several successful fundraising initiatives to support its clinical and preclinical programs.
“While we ended 2024 with $1.2 million in cash and cash equivalents, we’ve since enhanced our financial foundation through additional financing activities,” Hadar noted. “Since the reporting date, we’ve secured approximately $9.1 million in gross proceeds, or about $7.9 million net of transaction costs, through a priced offering, warrant inducement transaction, and warrant exercises.”
This capital extends Silexion’s operational runway and supports the advancement of its clinical pipeline. The company has also streamlined its balance sheet by retiring a promissory note through a combination of cash and share issuances, completed in March 2025.
“Our capital allocation strategy remains focused on advancing our most promising programs, particularly SIL204, which has shown such encouraging results,” said Hadar. “The majority of our resources will be dedicated to completing the necessary preclinical work, including toxicology studies, to prepare SIL204 for clinical trials.”
Charting the Path Forward
Silexion is poised to share its next chapter at the upcoming NeauxCancer Conference in New Orleans later this month. The company will unveil its expanded development strategy for SIL204, translating the promising preclinical findings into a comprehensive clinical roadmap.
“The data we’ve gathered has opened exciting new possibilities for SIL204’s development,” Hadar explained with evident enthusiasm. “We’ve crafted a strategy that not only builds on the remarkable tumor-reducing effects we’ve observed but also explores SIL204’s potential against metastatic disease—one of cancer treatment’s greatest challenges.”
According to Hadar, this expanded vision reflects Silexion’s core mission: “Every advancement brings us closer to our ultimate goal—developing therapies that can transform outcomes for patients battling these notoriously difficult KRAS-driven cancers. When you see tumor reduction of 70%-80% in models that closely mimic human disease, it fuels our determination to move this therapy forward as efficiently as possible.”
Recent News Highlights from Silexion:
- Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
- Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
- Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Subscribe for More Articles Like This
*DISCLAIMER: This article was published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This article contains and is a form of paid promotional content for to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms